Published in Int J Exp Pathol on December 01, 2004
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation (2011) 1.16
Breast tumor microenvironment: proteomics highlights the treatments targeting secretome. J Proteome Res (2008) 0.90
Matricellular proteins produced by melanocytes and melanomas: in search for functions. Cancer Microenviron (2008) 0.84
Regulation of ROCK1 via Notch1 during breast cancer cell migration into dense matrices. BMC Cell Biol (2012) 0.81
The myoepithelial cell layer may serve as a potential trigger factor for different outcomes of stage-matched invasive lobular and ductal breast cancers. Int J Biol Sci (2011) 0.81
Destructive impact of T-lymphocytes, NK and Mast cells on basal cell layers: implications for tumor invasion. BMC Cancer (2013) 0.77
Tenascin C and its modulatory role in tumor progression in systemic malignancies. Cytotechnology (2013) 0.75
In situ malignant transformation and progenitor-mediated cell budding: two different pathways for breast ductal and lobular tumor invasion. J Cancer (2011) 0.75
Agonists and knockdown of estrogen receptor β differentially affect invasion of triple-negative breast cancer cells in vitro. BMC Cancer (2016) 0.75
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
TGF-beta signaling in tumor suppression and cancer progression. Nat Genet (2001) 11.64
Matrix metalloproteinases: they're not just for matrix anymore! Curr Opin Cell Biol (2001) 4.99
Biochemical characterization of human collagenase-3. J Biol Chem (1996) 3.52
Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res (2000) 3.41
Proteinases of the mammary gland: developmental regulation in vivo and vectorial secretion in culture. Development (1991) 3.09
Laminin mediates tissue-specific gene expression in mammary epithelia. J Cell Biol (1995) 2.83
Tenascin: cDNA cloning and induction by TGF-beta. EMBO J (1988) 2.01
The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer (2000) 1.71
Tenascin-C in development and disease: gene regulation and cell function. Matrix Biol (2000) 1.40
Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clin Cancer Res (1995) 1.40
Matrix metalloproteinase-2 is associated with tenascin-C in calcific aortic stenosis. Am J Pathol (2001) 1.33
Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer (1998) 1.32
Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer (2003) 1.21
Oxygen-mediated regulation of gelatinase and tissue inhibitor of metalloproteinases-1 expression by invasive cells. Exp Cell Res (2001) 1.21
Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol (2002) 1.16
The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol (2001) 1.15
Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. Localization of active regions using recombinant tenascin fragments. J Cell Sci (1995) 1.15
Analysis of MT1-MMP and MMP2 expression in human gastric cancers. Int J Cancer (1997) 1.12
Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol (2003) 1.12
Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis (1999) 1.10
Synthesis and degradation of basement membranes and extracellular matrix and their regulation by TGF-beta in invasive carcinomas (Review). Int J Oncol (2001) 1.09
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer (2002) 1.08
Consequences of altered TGF-beta expression and responsiveness in breast cancer: evidence for autocrine and paracrine effects. Oncogene (2002) 1.06
Modulation of myoepithelial-associated alpha6beta4 integrin in a breast cancer cell line alters invasive potential. Exp Cell Res (1997) 1.03
Adhesion modulation by antiadhesive molecules of the extracellular matrix. Exp Cell Res (2000) 0.98
Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer (2000) 0.97
Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells. Virchows Arch (1999) 0.97
Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression. Breast Cancer Res Treat (1997) 0.94
A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. Am J Pathol (2001) 0.93
Fibroblasts promote breast cancer cell invasion by upregulating tumor matrix metalloproteinase-9 production. Surgery (2002) 0.91
Tenascin-A marker for the malignant potential of preinvasive breast cancers. Gynecol Oncol (2000) 0.89
Expression of tenascin-C in stromal cells of the murine uterus during early pregnancy: induction by interleukin-1 alpha, prostaglandin E(2), and prostaglandin F(2 alpha). Biol Reprod (2000) 0.85
Mammary epithelial cell differentiation in vitro is regulated by an interplay of EGF action and tenascin-C downregulation. J Cell Sci (1995) 0.85
Differential expression of tenascin-C and tenascin-X in human astrocytomas. Acta Neuropathol (1997) 0.85
Tenascin induction in tenascin nonproducing carcinoma cell lines in vivo and by TGF-beta 1 in vitro. J Cell Physiol (1994) 0.79
Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest (2004) 2.76
Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am J Physiol Heart Circ Physiol (2003) 1.74
Tenascin-C synthesized in both donor grafts and recipients accelerates artery graft stenosis. Cardiovasc Res (2007) 1.48
Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol (2005) 1.46
Method of cell transplantation promoting the organization of intraarterial thrombus. Circulation (2005) 1.40
Pitavastatin regulates helper T-cell differentiation and ameliorates autoimmune myocarditis in mice. Cardiovasc Drugs Ther (2013) 1.38
Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer (2003) 1.21
A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest (2007) 1.19
A crucial role of mitochondrial Hsp40 in preventing dilated cardiomyopathy. Nat Med (2005) 1.19
Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol (2002) 1.16
Tenascin C induces epithelial-mesenchymal transition-like change accompanied by SRC activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol (2011) 1.16
The targeted disruption of the MYPT1 gene results in embryonic lethality. Transgenic Res (2005) 1.12
Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol (2003) 1.12
Characterization and function of MYPT2, a target subunit of myosin phosphatase in heart. Cell Signal (2006) 1.11
Tenascin-C may aggravate left ventricular remodeling and function after myocardial infarction in mice. Am J Physiol Heart Circ Physiol (2010) 1.08
Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol (2006) 1.07
Inhibition of Rho family GTPases by Rho GDP dissociation inhibitor disrupts cardiac morphogenesis and inhibits cardiomyocyte proliferation. Development (2002) 1.05
Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol (2007) 1.05
Thrombin-cleaved osteopontin levels in synovial fluid correlate with disease severity of knee osteoarthritis. J Rheumatol (2010) 1.04
T-box 2, a mediator of Bmp-Smad signaling, induced hyaluronan synthase 2 and Tgfbeta2 expression and endocardial cushion formation. Proc Natl Acad Sci U S A (2009) 1.04
Matricellular proteins: new molecular targets to prevent heart failure. Cardiovasc Ther (2011) 1.04
The dynamic expression of tenascin-C and tenascin-X during early heart development in the mouse. Differentiation (2003) 1.03
A peptide derived from tenascin-C induces beta1 integrin activation through syndecan-4. J Biol Chem (2007) 1.02
Tenascin-C enhances crosstalk signaling of integrin αvβ3/PDGFR-β complex by SRC recruitment promoting PDGF-induced proliferation and migration in smooth muscle cells. J Cell Physiol (2011) 1.01
Interleukin-1 receptor antagonist inhibits the expression of vascular endothelial growth factor in colorectal carcinoma. Oncology (2005) 1.00
Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res (2007) 0.96
Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J (2007) 0.96
Densin-180, a synaptic protein, links to PSD-95 through its direct interaction with MAGUIN-1. Genes Cells (2002) 0.95
MMP-2 expression is associated with rapidly proliferative arteriosclerosis in the flexor tenosynovium and pain severity in carpal tunnel syndrome. J Pathol (2005) 0.93
Deficiency of tenascin C attenuates allergen-induced bronchial asthma in the mouse. Eur J Immunol (2006) 0.92
High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol (2009) 0.92
Imatinib mesylate prevents cerebral vasospasm after subarachnoid hemorrhage via inhibiting tenascin-C expression in rats. Neurobiol Dis (2012) 0.91
Degradation of tenascin-C and activity of matrix metalloproteinase-2 are associated with tumor recurrence in early stage non-small cell lung cancer. Clin Cancer Res (2002) 0.90
Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation (2002) 0.90
α9β1 integrin-mediated signaling serves as an intrinsic regulator of pathogenic Th17 cell generation. J Immunol (2011) 0.90
Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol (2005) 0.89
Thrombin-cleaved osteopontin in synovial fluid of subjects with rheumatoid arthritis. J Rheumatol (2009) 0.88
Regulation of tenascin-C expression by tumor necrosis factor-alpha in cultured human osteoarthritis chondrocytes. J Rheumatol (2007) 0.88
Dynamic expression of tenascin-C after myocardial ischemia and reperfusion: assessment by 125I-anti-tenascin-C antibody imaging. J Nucl Med (2010) 0.88
Tenascin-C is an essential factor for neointimal hyperplasia after aortotomy in mice. Cardiovasc Res (2005) 0.88
Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol (2004) 0.88
Regenerating axons emerge far proximal to the coaptation site in end-to-side nerve coaptation without a perineurial window using a T-shaped chamber. Plast Reconstr Surg (2006) 0.87
Rho kinases regulate endothelial invasion and migration during valvuloseptal endocardial cushion tissue formation. Dev Dyn (2006) 0.87
New insights into the developmental mechanisms of coronary vessels and epicardium. Int Rev Cell Mol Biol (2013) 0.87
Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure. J Card Fail (2009) 0.86
Increased expression of matrix metalloproteinase-2 in nasal polyps. Acta Otolaryngol (2004) 0.86
Circulating level of large splice variants of tenascin-C is a marker of piecemeal necrosis activity in patients with chronic hepatitis C. Liver Int (2006) 0.85
Tenascin-C induces prolonged constriction of cerebral arteries in rats. Neurobiol Dis (2013) 0.85
Prognostic value of serum tenascin-C levels on long-term outcome after acute myocardial infarction. J Card Fail (2012) 0.85
Tenascin-C is expressed in abdominal aortic aneurysm tissue with an active degradation process. Pathol Int (2011) 0.85
Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg (2007) 0.85
Tenascin-C causes neuronal apoptosis after subarachnoid hemorrhage in rats. Transl Stroke Res (2014) 0.85
Expression of large tenascin-C splice variants by hepatic stellate cells/myofibroblasts in chronic hepatitis C. J Hepatol (2006) 0.84
Cerebrospinal fluid tenascin-C in cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg Anesthesiol (2011) 0.83
Cerebrospinal fluid tenascin-C increases preceding the development of chronic shunt-dependent hydrocephalus after subarachnoid hemorrhage. Stroke (2008) 0.83
Histopathological findings in a human carotid artery after stent implantation. Case report. J Neurosurg (2003) 0.83